Upstream Bio reported a robust cash position of $341.5 million, sufficient to support operations through 2027, as it prepares to initiate Phase 3 trials for severe asthma and CRSwNP in early 2027. The promising efficacy demonstrated in Phase 2 trials further bolsters investor confidence, contributing to a recent share price increase.
Upstream Bio Inc. (NASDAQ: UPB) experienced a share price decline as recent clinical trial developments raised investor concerns. The stock's downward movement signals uncertainty about the future prospects of ongoing trials, which could impact revenue and market confidence.
